IL-6 levels displayed a positive correlation with irAEs related intestinal toxicity during immunotherapy, IL-6 pathway blockade significantly reduced intestinal damage whereas improved therapeutic outcomes in liver cancer patients (26). This evidence concerns the gene IL6 and liver cancer.